Receipt date: 06/08/2009

£2**£499£8**NIGAHLIN648

Sheet 1 of 1

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
11340-007-999	10/549,958	
APPLICANT		
Ensoli		
FILING DATE	GROUP	
September 15, 2005	1648	
Deptember 15, 2005	1070	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR

		FOREIGN	PATENT DOCUMENTS		
*EXAMINER INITIAL	FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	т

NON PATENT LITERATURE DOCUMENTS				
*EXAMINER Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	C07	Barker et al., "Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals," AIDS, 1998, 12(9):1117-1118.		
	C08	Deeks et al., "HIV-1 protease inhibitors. A review for clinicians," JAMA, 1997, 277(2):145-153.		
	C09	Dowell <i>et al.</i> , "Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors," J Biol Chem., 2000, 275(52):41325-41332.		
	C10	Flexner C., "HIV-protease inhibitors," N Engl J Mcd., 1998, 338(18):1281-1292.		
	C11	Lu et al., "HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism," Blood, 2000, 96(1):250-258.		
	C12	Weichold <i>et al.</i> , "HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells," J Hum Virol., 1999, 2(5):261-269.		

EXAMINER /Nicole Kinsey/ DATE CONSIDERED 09/29/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.